Imaging cytometry: the advantages of hybrid technology in support - - PowerPoint PPT Presentation

Imaging cytometry: the advantages of hybrid technology in support

• f drug discovery

Richard Hughes EBF Open Meeting 2017

• Technological advances in cytometry – pros and cons
• ZellScanner chipcytometry technology - how does it work and what it can offer over conventional flow cytometry
• Examples of chipcytometry to support drug discovery
• Validation of chipcytometry for use in clinical application

Imaging cytometry: the advantages of hybrid technology in support of drug discovery

Overview

Nov 2017/ EBF 10th Open Symposium

http://www.merckmillipore.com/GB/en/life- science-research/cell-analysis/amnis-imaging- flow-cytometers/

– ImageStream/FlowCyte (Amnis, MerckMillipore)

5

Nov 2017/ EBF 10th Open Symposium

Advances in flow cytometry

https://www.fluidigm.com/products/cytof

– CyTOF Mass Cytometer (Fluidigm)

– ImageStream/FlowCyte – CyTOF Mass Cytometer – Chipcytometry, Zellkraftwerk GmbH

Advances in flow cytometry

6

Name ZellScanner ONE™ Cytobot™ System Benchtop instrument Automated system (Tecan) Operation Manual Fully automated, 24/7 Application Exploratory / Phase I trials Phase II/III trials

Nov 2017/ EBF 10th Open Symposium

Manufacturer MerckMillipore Fluidigm/DVS Sony Zellkraftwerk Zellkraftwerk

Instrument ImageStream-X MKII CyTOF 2 SP6800 Spectral Analyzer ZellScannerONE Cytobot Technology imaging flow cytometry mass cytometry spectral cytometry Chipcytometry ChipCytometry Technology Features Multiplexing: theoretical limit Max 10 colors 100 25 unlimited unlimited Multiplexing: actual limit 12 40 19 100 100 subcellular localization ++

• +

+ sample storage 1-5 days 1-5 days 1-5 days at least 20 months at least 20 months cell-loss / drop out rate 10% 1.00% ? <0.5% <0.5% tissue cytometry

• Coming soon
• +

Coming soon Instrument Features cells/second 5,000 1,000 10,000 2,000 6,000 de-novo setup of a 15-marker panel not possible 3 month 4 month <1 day <1 day Total cost of ownership (USD) Basic instrument ≈400,000 ≈590,000 ≈400,000 280,000 980,000 Energy supply ≈2,000 ≈8,000 ≈2,000 2,000 4,000 Argon gas supply not required 60,000 not required not required not required Maintenance Contract ≈40,000 ≈50,000 ≈35,000 ≈18,000 ≈50,000 Pros & Cons biggest pros statistical microscopy with many morphological parameters many publications by inventor available discrimination of fluorescent proteins / fluorochromes best instrument for low cell numbers and precious samples precious samples: option for 20 months storage biggest cons limited to max. 10 colors / when more than 6 colors are required cumbersome panel development proprietary labels required / dedicated user necessary cumbersome panel development bench-top instrument has medium-low sample throughput // fully automated system is expensive price

Advances in flow cytometry – Pros and Cons

Nov 2017/ EBF 10th Open Symposium

ZellScanner Chipcytometry technology

How does it work and what it can offer over conventional flow cytometry

Nov 2017/ EBF 10th Open Symposium

ZellScanner Chipcytometry technology

9

How does it work and what can if offer over conventional flow cytometry

Product ZellSafe™ Cells ZellSafe™ Rare ZellSafe™ Tissue Specimen cell suspension rare cells (<0.02%) sections Loading capacity 40-100 µL 40-300 µL 6 biopsies or 2x1cm section Total cell number typically 250,000 typically 1,000,000 tissue-dependent

Nov 2017/ EBF 10th Open Symposium

ZellScanner Chipcytometry technology

10

How does it work and what can it offer over conventional flow cytometry

Nov 2017/ EBF 10th Open Symposium

PBMC Image from ‘Validation of Treg, Th17 and Plasma Cell Assays’

• J. Detmers, A. Mirenska, C. Hennig, S. Poelmans, M. Van Roy, T. Van Bogaert

AAPS, NBS Poster 2017 conference poster M1025

ZellScanner Chipcytometry technology

11

How does it work and what can it offer over conventional flow cytometry

Conventional Flow Cytometry ChipCytometry

Sample Stability 1-3 days ≈ 24 months Markers/Sample 8-16 > 100 Re-interrogate Sample?

X

Nov 2017/ EBF 10th Open Symposium

ZellScanner Chipcytometry versatility

Insert your date / confidentiality text here 12

What can it offer over conventional flow cytometry

Cell Suspensions:

• PBMC / whole blood
• bone marrow
• CSF
• bronchoalveolar lavage (BAL)
• cell lines
• sorted cells
• digested tissues (lung, gut, tonsil, spleen, liver)
• Nasal scrapes

Tissue / Sections

• lung
• gut
• bone
• cancer biopsy
• skin
• bone sections

Stain the same cells repeatedly Identify infiltrating cell types in carcinoma tissue

Maroz et al.Leukemia, 2014

Muller, M et al, Fraunhofer ITEM

Nov 2017/ EBF 10th Open Symposium

Compatible Specimens

courtesy of Definiens AG, Munich

Examples of chipcytometry to support drug discovery

Low sample volume Rare events from small cell numbers Sample storage and re-interrogation

Analysis of B cells from Cynomolgus macaque Lymph Node Aspirates

14

Aim: To demonstrate target engagement in CD20+ B cells from lymph nodes

– Lymph node aspirates were collected by CRO following dosing of the animals with 1 mg/kg, 10 mg/kg of drug or Vehicle – Time points: 24, 48, 96, 168, 672 (4 weeks), 1032 (6 weeks + 1 day) and 1680 hours (10 weeks). – The cells from the aspirates were placed immediately into a tube and 25 µl of sterile PBS was added. – Each tube was then shipped to GSK Stevenage on ice for processing. where samples were centrifuged, the supernatant collected for PK analysis, and the cells re-suspended in 50 µL of Zellkraftwerk wash buffer.

1

• Apply lymph node cells to chip
• scan background

2

• PE-CD20 to identify B cells
• Scan, followed by photobleaching

3

• Add PE-drug
• Addition of PE-conjugated drug acts in competition to bound

dosed drug

• Scan, followed by photobleaching

4.

• PE-non competitive anti-target
• Will bind to target receptor regardless of whether drug is

bound, thus gives an indication of whether receptor is internalised or has been shed

Nov 2017/ EBF 10th Open Symposium

Joanne Thompson, Exploratory Biomarkers, BIB, IVIVT, GSK

Analysis of B cells from Cynomolgus macaque Lymph Node Aspirates

15

Target Target

24 hours post dose

Vehicle 10 mg/kg Vehicle 1 mg/kg 10 mg/kg 24 hrs 48 hrs 168 hrs

Nov 2017/ EBF 10th Open Symposium

Joanne Thompson, Exploratory Biomarkers, BIB, IVIVT, GSK

PE Conjugated Drug CD20

Add storage buffer to the chip - store for up to 2 years at 0-10 C Convert the files to fcs and treat as normal flow data within FlowJo Using GIMP, can visualise overlays of the different stains on the cells

Validation of chipcytometry to support clinical studies

Nov 2017/ EBF 10th Open Symposium

Validation of chipcytometry to support clinical studies

17

– GSK2831781 is a monoclonal antibody being developed by GlaxoSmithKline for the treatment of Psoriasis. The antibody targets the T cell activation marker LAG-3, which is mainly expressed in inflamed tissues. GSK2831781 entered this Phase 1 clinical trial, initially in healthy subjects, in 2014 with the first Psoriasis subjects being dosed in 2016. – Samples from Clinical studies are currently analysed by flow cytometry using two 8-colour panels. Even with a limited number of Clinical Sites this has still proved to be both technically and logistically challenging and would be impossible moving forward into Phase II studies. – To determine if Chipcytometry would offer an alternative solution to measure PD biomarkers for LAG-3, a subset of samples collected from patients enrolled in the Psoriasis cohorts of the study will be collected and stored for analysis using the validated 12-colour Chipcytometry assay.

Sample analysis Full regulatory validation Pilot study

Nov 2017/ EBF 10th Open Symposium

LAG-3 Chipcytometry Pilot Study

Study objective: To assess feasibility of measuring LAG-3 on PBMCs isolated from whole blood

Nov 2017/ EBF 10th Open Symposium

18

– Deliverables – Compare 2 LAG-3 antibodies (Clone 3DS223H - eBioScience and Clone REA351 - Miltenyi Biotec) – Evaluate LAG-3 expression on unstimulated and IL- 12/18 PBMCs (n=3 donors) – Antibody Panel: CD3, CD4, CD8, CD45RA, LAG-3 – Enumerate percentage of LAG-3+ cells – Direct comparison with flow was not performed

LAG-3 Chipcytometry Pilot Study

Study objective: To assess feasibility of measuring LAG-3 on PBMCs isolated from whole blood

19

– Enumerate percentage of LAG-3+ cells (sensitivity)

Nov 2017/ EBF 10th Open Symposium

Validation of chipcytometry to support clinical studies

20

• For all validation experiments, PBMCs from 5 different healthy donors stimulated with IL-12/IL-18
• After stimulation, PBMCs from all tubes per donor will be pooled and loaded onto ZellSafeTM chips
• One biological replicate is defined as PBMCs isolated from one healthy donor and pooled after stimulation.
• Multiple chips of the same production lot containing the same biological replicate are used for independent repeated

measurements (hereafter referred to as technical replicates).

• Each chip undergoes a quality inspection and only chips that pass the quality control are used to conduct the experiments.

Validation is closely performed in line with validation criteria published by O’Hara et al., 2011.

Nov 2017/ EBF 10th Open Symposium

Validation of chipcytometry to support clinical studies

21

Validation is closely performed in line with validation criteria published by O’Hara et al., 2011.

Parameter Details

Intra Assay Precision

%CV of all reportable parameters when the assay is performed on 3 technical replicates, and this will be repeated for 5 different donors. A %CV <25% for all 5 donors is acceptable

Inter Assay Precision

Not performed

Stability

Baseline values at time point 0 are identical with the values calculated for intra-assay precision validation. The 4 ‘stability time point’ chips per donor were stored at 4°C in the dark. After 2, 6 and 12 months, one sample per donor is assayed, respectively. The 4th is

• biobanked. 80% of the donors the target cell count is within 25% from the baseline mean

Drug Interference

Cells are incubated with drug at room temperature for 30 min (eg. Cmax, Ctrough). Interference was analysed by comparing results of spiked samples with 3 unspiked replicates of the same volunteer and calculating the % difference.

Cross-comparison Chipcytometry - FACS

Intra Assay Precision

22

Nov 2017/ EBF 10th Open Symposium

Inter-Assay Precision

23

Nov 2017/ EBF 10th Open Symposium

Stability and cross-comparison

24

Poster 59, SUNDAY, OCTOBER 8, 2017 ICCS Meeting 2017, Arizona

% of CD3+ Chip cytometry demonstrated good concordance with standard flow for both functional and phenotypic markers

Nov 2017/ EBF 10th Open Symposium

– Low sample volume – Rare events from small cell numbers – Long term sample storage and re-interrogation

The advantages of Chip Cytometry in support of drug discovery

Nov 2017/ EBF 10th Open Symposium

– Low sample volume – Rare events from small cell numbers – Long term sample storage and re-interrogation

The advantages of Chip Cytometry in support of drug discovery

Nov 2017/ EBF 10th Open Symposium

Acknowledgements

Joanne Thompson Fiona Germaschewski Karen Leavens Jan Detmers www.zellkraftwerk.com All animal studies were ethically reviewed and carried out in accordance with Animals (Scientific Procedures) Act 1986 and the GSK Policy on the Care, Welfare and Treatment of Animals.